◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2500

Venus Medtech (Hangzhou) Inc. (2500) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-10

Venus Medtech (Hangzhou) Inc. (2500) operates in the Medical Devices industry and is headquartered in Hangzhou, China with about 560 employees. Its market capitalization is roughly CNY 467 million. In the fiscal year ended 2025-12-31, 2500 reported CNY 307M in revenue and (CNY 408M) in net income.

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.

Interactive charts & full statements →

2500 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total RevenueCNY 307MCNY 471MCNY 491MCNY 406M
Gross ProfitCNY 212MCNY 368MCNY 389MCNY 314M
Operating Income (EBIT)(CNY 327M)(CNY 347M)(CNY 571M)(CNY 635M)
Net Income(CNY 408M)(CNY 714M)(CNY 704M)(CNY 1.1B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2500 Free Cash Flow History

2500 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 2.5BCNY 3.2BCNY 4.4BCNY 5.3B
Total LiabilitiesCNY 757MCNY 1.0BCNY 1.5BCNY 1.7B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2500 viewer.

Other Companies in Medical Devices

← 2499All “0-9” companies2501 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.